Ataxias are a heterogeneous group of neurological disorders affecting individuals of all age groups and are characterized by the incoordination of voluntary movements. Features can include cerebellar dysfunction involving disturbance of stance, gait, eye movements, muscle tone, skilled movements and speech.

Genetic testing for hereditary ataxias can present challenges in daily clinical practice due to significant clinical and genetic heterogeneity. Ataxia can be isolated or part of a multisystemic syndromic presentation, age of onset and severity of symptoms is highly variable, and inheritance can be autosomal dominant, autosomal recessive, X-linked, or mitochondrial. The most common hereditary forms of ataxia include the autosomal dominant spinocerebellar ataxias (SCAs) and the autosomal recessive Friedreich ataxia which are caused by trinucleotide repeat expansions. Fragile X-associated tremor/ataxia syndrome (FXTAS), caused by a premutation in the FMR1 gene, is the most common X-linked cause of cerebellar ataxia. Worldwide SCA1, 2, 3, 6, and 7 explain 50-60% of all cases of autosomal dominant ataxia, while other known SCA subtypes are rare (<1%). In general, recessive ataxias often present as multisystem disorders, while autosomal dominant ataxias are typically restricted to the central nervous system.

Being able to provide a genetic diagnosis allows for the opportunity for genetic counseling, long-term investigations and development of therapeutic strategies, and has implications for patient management and prognosis.

**Genetic Testing Options for Ataxia**
- Repeat expansion testing
- Exome-based sequencing (565 genes analyzed)

### Our Ataxia Repeat Expansion Panel includes repeat expansion testing for 12 genes associated with ataxia.

<table>
<thead>
<tr>
<th>Disorder</th>
<th>Gene</th>
<th>Normal repeat number</th>
<th>Uncertain/reduced penetrance repeat number</th>
<th>Full/high penetrance repeat number</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCA1 ATXN1</td>
<td>≤44 (CAT present), ≤35 (CAT absent)</td>
<td>36-38 (CAT absent)</td>
<td>≥45 (CAT present), ≥39 (CAT absent)</td>
<td></td>
</tr>
<tr>
<td>SCA2 ATXN2</td>
<td>≤31</td>
<td>32</td>
<td>≥33</td>
<td></td>
</tr>
<tr>
<td>SCA3 (Machado-Joseph disease) ATXN3</td>
<td>≤44</td>
<td>45-59</td>
<td>≥60</td>
<td></td>
</tr>
<tr>
<td>SCA6 CACNA1A</td>
<td>≤18</td>
<td>19</td>
<td>≥20</td>
<td></td>
</tr>
<tr>
<td>SCA7 ATXN7</td>
<td>≤18</td>
<td>19-36</td>
<td>≥37</td>
<td></td>
</tr>
<tr>
<td>SCA8 ATXN8OS</td>
<td>≤50</td>
<td>51-79</td>
<td>≥80</td>
<td></td>
</tr>
<tr>
<td>SCA10 ATXN10</td>
<td>≤32</td>
<td>33-799</td>
<td>≥800</td>
<td></td>
</tr>
<tr>
<td>SCA12 PPP2R2B</td>
<td>≤32</td>
<td>33-50</td>
<td>≥51</td>
<td></td>
</tr>
<tr>
<td>SCA17 TBP</td>
<td>≤40</td>
<td>41-48</td>
<td>≥49</td>
<td></td>
</tr>
<tr>
<td>DRPLA (Dentatorubral-pallidoluysian atrophy) ATN1</td>
<td>≤35</td>
<td>36-47</td>
<td>≥48</td>
<td></td>
</tr>
<tr>
<td>FXTAS (Fragile X-related tremor/ataxia syndrome) FMR1</td>
<td>5-44</td>
<td>45-54</td>
<td>55-200 (premutation)</td>
<td></td>
</tr>
<tr>
<td>FRDA (Friedreich ataxia) FXN</td>
<td>≤33</td>
<td>34-65</td>
<td>≥66</td>
<td></td>
</tr>
</tbody>
</table>
**Our Ataxia Exome includes analysis of 565 genes associated with ataxia.**

<table>
<thead>
<tr>
<th>Ataxia Exome</th>
<th>Autosomal Recessive Genes</th>
<th>Autosomal Dominant Genes</th>
<th>X-linked Genes</th>
</tr>
</thead>
</table>
| The Ataxia Exome includes exome sequencing and analysis of a predefined set of 565 genes associated with ataxia and assembled by research and clinical experts in the field. These include genes known to be associated with ataxia as the predominant feature, genes associated with ataxia as part of the phenotype, and genes speculated to be involved in an ataxia phenotype based on expert opinion. | Over 230 ataxia genes including:  
- Spastic paraplegia  
- Joubert syndrome  
- Cereoid lipofuscinosis  
- Mitochondrial disorders  
- Inborn errors of metabolism  
- Muscular dystrophy-dystroglycanopathies  
- Mendelian Genetic syndromes  
- And Many More | Over 70 genes including:  
- Spinocerebellar ataxias  
- Mendelian genetic syndromes  
- And Many More | Including:  
- Epileptic encephalopathy  
- Intellectual disability  
- Mendelian genetic syndromes  
- And Many More |

For a list of the 565 genes analyzed, please visit our website.

**Analysis and Methods**

**Repeat Expansion Panel**
Repeat sizing is performed by standard flanking-PCR (F-PCR) and repeat primed PCR (RP-PCR) followed by capillary electrophoresis. F-PCR amplifies across the repeat region while RP-PCR amplifies within the repeat region. RP-PCR will detect large expansions that may not be detected by F-PCR and provides more accurate repeat sizing information. RP-PCR is performed using a fluorescently labeled primer specific to the target of interest, a ‘repeat primer’ consisting of multiple repeats in tandem, and an anchor primer specific to a tail attached to the repeat primer. A ‘ladder’ of repeat size products is generated and sizing determined by counting the number of peaks of the ladder (Warner et al., 1996. J Med Genet. 33(12):1022-1026). Expansions larger than 100 repeats for all the repeats tested can be detected but may not be sized by this test. SCA10 fully penetrant alleles (>800) will not be differentiated from reduced penetrant alleles that are >100 repeats. For repeat sizes in the normal range the accuracy of the assay is +/- 1 repeat. For repeat sizes in the uncertain significance/reduced penetrance range and full mutation expansions that can be sized the accuracy of the assay is +/- 3 repeats.

**Ataxia Exome**
Of the thousands of variants identified by exome sequencing, a list of variants that are located within a predefined set of 565 genes that have been associated with ataxia is generated. Variants within this gene list are analyzed. In some cases, exome sequencing data may also be used to detect larger copy number variations (CNVs) such as whole or partial gene deletions/duplications. The sensitivity of exome sequencing to detect intragenic deletions/duplications >20bp in size is not currently known. For cases without a clearly pathogenic variant identified in the predefined list of 565 genes, an additional analysis of previously reported pathogenic variants and truncating variants in known disease genes (present in the HGMD database) will be performed. For variants outside of the predefined list of 565 genes, only those considered to be the likely cause of the patient’s phenotype will be reported. Mutations in genes unrelated to the individual's reported phenotype are considered secondary or incidental findings. Secondary or incidental findings will not be reported in the Ataxia Exome, unless they occur within the predefined list of 565 genes. Most variants identified as part of exome sequencing will NOT undergo interpretation by a laboratory staff member. Only those variants considered to be potentially relevant to the patient's condition are reviewed by a team of Board-Certified PhD geneticists, MD geneticists, and genetic counselors who will determine the likelihood of the variant being related to the patient's disorder based on the phenotypic information provided by the ordered clinician.

Exome sequencing is performed using the Agilent SureSelect Clinical Research Exome kit that is designed to target the exome with greater coverage of known disease-associated genes. Sequencing is performed using the Illumina technology and reads are aligned to the reference sequence. Approximately 97-98% of exons in the genes of interest are targeted at a minimum depth of 10X in the diagnostic Ataxia Exome. Our analytical pipeline presents variants on only the preselected 565 genes implicated in ataxia. Variants are identified and evaluated using a custom collection of bioinformatic tools and comprehensively interpreted by our team of directors and genetic counselors. All pathogenic and likely pathogenic variants are confirmed by Sanger sequencing.

**Re-analysis of the Ataxia Exome**
As new gene discoveries and associations are reported in the literature, we can review past cases for findings in these genes. Re-analysis of exome sequencing data is available upon request. Reanalysis can be performed once at no additional charge; additional charges may apply for further reanalysis requests.
### Pricing and Turnaround Times

**Ataxia Repeat Expansion Panel**
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $1250
- CPT codes: 81401
- Turn-around time: 2-4 weeks

**Repeat Expansion Testing for a Single Ataxia Disorder**
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $750
- CPT codes: 81401
- Turn-around time: 2-4 weeks

**Ataxia Exome**
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $4000
- CPT codes: 81415
- Turn-around time: 6 weeks

**Note:** We do not bill insurance directly for this specific test

**Comprehensive Ataxia Testing CONCURRENT (Ataxia Repeat Expansion Panel & Ataxia Exome)**
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $5000
- CPT codes: 81401, 81415
- Turn-around time: 6 weeks

**Note:** We do not bill insurance directly for this specific test

**Comprehensive Ataxia Testing REFLEX (Ataxia Repeat Expansion Panel with reflex to Ataxia Exome)**
- Sample specifications: 3 to 10 cc of blood in a purple top (EDTA) tube
- Cost: $1250 for Ataxia Repeat Expansion Panel
- Cost: $3750 for Ataxia Exome
- CPT codes: 81401, 81415
- Turn-around time: 6-8 weeks

**Note:** We do not bill insurance directly for this specific test

---

For more information about our testing options, please visit our website at dnatesting.uchicago.edu or contact us at 773-834-0555.

---

**Additional Resources for Hereditary Ataxias**

Research studies on the genetics of ataxia are available in the laboratory of Dr. Margit Burmeister at the University of Michigan. For more information please visit http://www.hg.med.umich.edu/faculty/margit-burmeister-phd or contact Study Coordinator, Erin Sandford, Ph.D. esandfor@umich.edu.

**References:**


---

Committed to CUSTOMIZED DIAGNOSTICS, TRANSLATIONAL RESEARCH & YOUR PATIENTS’ NEEDS